$10.190
+0.194 (+1.90%)收盤時
BNR 資訊
BNR 事件
Company Reports Q4 Revenue of RMB126.3M
Reports Q4 revenue RMB126.3M vs. RMB126M last year.
JPMorgan Lowers Brenntag Price Target to EUR 44, Maintains Underweight Rating
JPMorgan lowered the firm's price target on Brenntag to EUR 44 from EUR 45.40 and keeps an Underweight rating on the shares.
Burning Rock Receives Approval for OncoGuide OncoScreen Plus CDx System in Japan
Riken Genesis and Burning Rock Biotech (BNR) announced that the OncoGuide OncoScreen Plus CDx System based on OncoScreen Plus to be used as a companion diagnostic for AstraZeneca's (AZN) capivasertib has received manufacturing and marketing approval from Japan's Ministry of Health, Labour and Welfare.
Burning Rock Biotech reports Q4 EPS (RMB 0.79) vs. (RMB 1.58) last year
Reports Q4 revenue RMB 126.02M vs. RMB 121.09M last year. Cash, cash equivalents, restricted cash were RMB 522.2M.
Burning Rock Biotech, Dizal announce NMPA approval for sunvozertinib CDx
Burning Rock Biotech and Dizal jointly announced that the companion diagnostic, or CDx, for EGFR exon 20 insertion mutation, or exon20ins, for sunvozertinib, developed through their collaboration, has been approved by the National Medical Products Administration, or NMPA, of China. This marks the first co-developed NGS-based CDx for lung cancer approved by NMPA since the release of the CDx guideline in China. The approval of this CDx test is the result of the simultaneous development of Burning Rock's independently developed LungCure CDx and Dizal's innovative EGFR exon20ins targeted therapy - sunvozertinib, providing an innovative precision treatment solution for non-small cell lung cancer patients with EGFR exon20ins.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。